See more : PFA Invest Balance B (PFIBAB.CO) Income Statement Analysis – Financial Results
Complete financial analysis of Celcuity Inc. (CELC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Celcuity Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- BuzzFeed, Inc. (BZFDW) Income Statement Analysis – Financial Results
- XCana Petroleum Corporation (XCPT) Income Statement Analysis – Financial Results
- SA Entreparticuliers.com (ALENT.PA) Income Statement Analysis – Financial Results
- Fineland Living Services Group Limited (9978.HK) Income Statement Analysis – Financial Results
- Swicorp Wabel Reit Fund (4345.SR) Income Statement Analysis – Financial Results
Celcuity Inc. (CELC)
About Celcuity Inc.
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 142.77K | 210.92K | 303.24K | 385.59K | 339.00K | 223.04K | 104.70K | 73.06K | 58.38K |
| Gross Profit | -142.77K | -210.92K | -303.24K | -385.59K | -339.00K | -223.04K | -104.70K | -73.06K | -58.38K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 60.59M | 35.29M | 25.76M | 7.68M | 6.27M | 6.33M | 4.98M | 3.06M | 2.01M |
| General & Administrative | 5.64M | 4.10M | 2.60M | 1.87M | 1.54M | 1.61M | 972.52K | 263.66K | 250.09K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.64M | 4.10M | 2.60M | 1.87M | 1.54M | 1.61M | 972.52K | 263.66K | 250.09K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 66.23M | 39.39M | 28.36M | 9.56M | 7.81M | 7.93M | 5.95M | 3.33M | 2.26M |
| Cost & Expenses | 66.23M | 39.39M | 28.36M | 9.56M | 7.81M | 7.93M | 5.95M | 3.33M | 2.26M |
| Interest Income | 2.45M | 1.13M | 13.26K | 82.11K | 446.10K | 448.83K | 152.88K | 18.02K | 268.00 |
| Interest Expense | 0.00 | 2.11M | 1.26M | 120.00 | 159.00 | 111.00 | 451.66K | 0.00 | 0.00 |
| Depreciation & Amortization | 142.77K | 210.92K | 303.24K | 385.59K | 339.00K | 223.04K | 104.70K | 73.06K | 58.38K |
| EBITDA | -58.31M | -39.18M | -28.05M | -9.17M | -7.47M | -7.71M | -5.85M | -3.26M | -2.20M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -66.23M | -39.39M | -28.36M | -9.56M | -7.81M | -7.93M | -5.95M | -3.33M | -2.26M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 2.45M | -978.95K | -1.25M | 81.99K | 445.94K | 451.72K | -298.79K | 18.02K | 268.00 |
| Income Before Tax | -63.78M | -40.37M | -29.61M | -9.47M | -7.36M | -7.48M | -6.25M | -3.31M | -2.26M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 978.95K | 959.12K | -385.47K | -338.84K | 451.83K | 48.18K | 0.00 | 0.00 |
| Net Income | -63.78M | -41.35M | -30.56M | -9.09M | -7.02M | -7.48M | -6.25M | -3.31M | -2.26M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.69 | -2.68 | -2.28 | -0.89 | -0.69 | -0.74 | -0.84 | -0.49 | -0.36 |
| EPS Diluted | -2.69 | -2.68 | -2.28 | -0.89 | -0.69 | -0.74 | -0.84 | -0.49 | -0.36 |
| Weighted Avg Shares Out | 23.68M | 15.42M | 13.38M | 10.27M | 10.23M | 10.12M | 7.46M | 6.72M | 6.31M |
| Weighted Avg Shares Out (Dil) | 23.68M | 15.42M | 13.38M | 10.27M | 10.23M | 10.12M | 7.46M | 6.72M | 6.31M |
Celcuity Inc. Schedules Release of Second Quarter 2023 Financial Results and Webcast/Conference Call
MINNEAPOLIS, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced that it will release its financial results for the second quarter 2023 after the stock...
Celcuity to Participate in the BTIG Virtual Biotechnology Conference 2023
MINNEAPOLIS, July 31, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced that Brian Sullivan, Chairman, Chief Executive Officer, and Co-founder of Celcuity, will participate in one-on-one...
Celcuity Set to Join Russell 2000 and 3000 Indexes
MINNEAPOLIS, MN / ACCESSWIRE / June 20, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, is set to join the Russell 2000® and 3000® Indexes at the conclusion of the 2023...
Celcuity to Participate in Upcoming Craig-Hallum and Jefferies Investor Conferences
MINNEAPOLIS, MN / ACCESSWIRE / May 24, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced that Brian Sullivan, Chairman, Chief Executive Officer, and Co-founder of Celcuity, will participate in...
Celcuity Inc. (CELC) Q1 2023 Earnings Call Transcript
Celcuity Inc. (NASDAQ:CELC ) Q1 2023 Earnings Conference Call May 15, 2023 4:30 PM ET Company Participants Robert Uhl - ICR Westwicke, IR Brian Sullivan - CEO and Co-Founder Vicky Hahne - CFO Conference Call Participants Maury Raycroft - Jefferies...
Celcuity Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Updates
Presented updated results for treatment-naïve patients from Phase 1b study of gedatolisib at the ESMO Breast Cancer Annual Congress - median progression free survival (PFS) was 48.6 months Presented nonclinical prostate cancer data at ASCO GU Cancers Symposium demonstrating the...
Celcuity Presents Updated Results from Phase 1b Study of Gedatolisib in Treatment-Naïve Patients at the 2023 ESMO Breast Cancer Annual Congress
Median progression free survival (PFS) was 48.6 months in treatment-naïve patients with HR+/HER2- advanced breast cancer who were treated with gedatolisib in combination with palbociclib and letrozole Median duration of response (DOR) was 46.9 months MINNEAPOLIS, MN / ACCESSWIRE /...
Celcuity Inc. Schedules Release of First Quarter 2023 Financial Results and Webcast/Conference Call
MINNEAPOLIS, MN / ACCESSWIRE / May 8, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced that it will release its financial results for the first quarter 2023 after the...
Celcuity to Present Updated Results for Treatment-Naïve Patients from Phase 1b Study of Gedatolisib at the 2023 ESMO Breast Cancer Annual Congress
MINNEAPOLIS, MN / ACCESSWIRE / May 8, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced publication of an abstract reporting updated results for treatment-naïve patients from the Phase 1b...
Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023
Gedatolisib demonstrated superior anti-proliferative potency and efficacy in endometrial, ovarian and cervical cancer cell lines compared to other PAM inhibitors evaluated regardless of PTEN, P13K, or AKT mutational status MINNEAPOLIS, MN / ACCESSWIRE / April 18, 2023 / Celcuity Inc....
Source: https://incomestatements.info
Category: Stock Reports